Key Points

• Myelofibrosis is a form of blood cancer which causes extensive scarring of the bone marrow, leading to low platelet production and increased risk of bleeding.
• Treating the condition is difficult - anaemia is a common side effect.
• A new drug, Momelotinib, approved by the Therapeutic Goods Administration in December, is giving patients hope.